|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/30/23 Y-mAbs Therapeutics, Inc. 10-K 12/31/22 106:10M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 2.63M
2: EX-4.4 Instrument Defining the Rights of Security Holders HTML 50K
3: EX-10.41 Material Contract HTML 39K
4: EX-10.42 Material Contract HTML 325K
5: EX-21.1 Subsidiaries List HTML 28K
6: EX-23 Consent of Expert or Counsel HTML 28K
7: EX-31.1 Certification -- §302 - SOA'02 HTML 36K
8: EX-31.2 Certification -- §302 - SOA'02 HTML 35K
9: EX-32.1 Certification -- §906 - SOA'02 HTML 31K
10: EX-32.2 Certification -- §906 - SOA'02 HTML 31K
16: R1 Document and Entity Information HTML 97K
17: R2 Consolidated Balance Sheets HTML 123K
18: R3 Consolidated Balance Sheets (Parenthetical) HTML 44K
19: R4 Consolidated Statements of Net Income (Loss) and HTML 98K
Comprehensive Income (Loss)
20: R5 Consolidated Statements of Changes in HTML 79K
Stockholders' Equity
21: R6 Consolidated Statements of Cash Flows HTML 103K
22: R7 Organization and Description of Business HTML 32K
23: R8 Basis of Presentation HTML 36K
24: R9 Summary of Significant Accounting Policies HTML 115K
25: R10 Product Revenue HTML 62K
26: R11 Net Loss Per Share HTML 42K
27: R12 Inventories HTML 60K
28: R13 Intangible Assets, Net HTML 32K
29: R14 Accrued Liabilities HTML 46K
30: R15 License Agreements and Commitments HTML 164K
31: R16 Stockholders' Equity HTML 41K
32: R17 Share-Based Compensation HTML 110K
33: R18 Related Party Transactions HTML 32K
34: R19 Income Taxes HTML 126K
35: R20 Other Benefits HTML 31K
36: R21 Gain From Sale of Priority Review Voucher HTML 31K
37: R22 Subsequent Events HTML 32K
38: R23 Summary of Significant Accounting Policies HTML 164K
(Policies)
39: R24 Summary of Significant Accounting Policies HTML 74K
(Tables)
40: R25 Product Revenue (Tables) HTML 56K
41: R26 Net Loss Per Share (Tables) HTML 40K
42: R27 Inventories (Tables) HTML 59K
43: R28 Accrued Liabilities (Tables) HTML 46K
44: R29 License Agreements and Commitments (Tables) HTML 132K
45: R30 Share-Based Compensation (Tables) HTML 101K
46: R31 Income Taxes (Tables) HTML 129K
47: R32 BASIS OF PRESENTATION - Accumulated deficit HTML 32K
(Details)
48: R33 BASIS OF PRESENTATION - Public offering (Details) HTML 41K
49: R34 BASIS OF PRESENTATION - Cash and cash equivalents HTML 31K
(Details)
50: R35 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 36K
Concentration of Credit Risk (Details)
51: R36 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 30K
Inventory (Details)
52: R37 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair HTML 46K
Value Measurement (Details)
53: R38 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 30K
Operating Leases (Details)
54: R39 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 30K
Revenue Recognition - Product revenue (Details)
55: R40 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 65K
Revenue Recognition - License revenue (Details)
56: R41 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 30K
Segment (Details)
57: R42 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 44K
Property and Equipment (Details)
58: R43 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 30K
Income Taxes (Details)
59: R44 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 31K
Research and development (Details)
60: R45 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Other HTML 33K
policies (Details)
61: R46 PRODUCT REVENUE - Disaggregation (Details) HTML 41K
62: R47 PRODUCT REVENUE - Discounts and Allowances HTML 71K
(Details)
63: R48 PRODUCT REVENUE - Concentrations (Details) HTML 44K
64: R49 NET LOSS PER SHARE - Basic and diluted (Details) HTML 56K
65: R50 NET LOSS PER SHARE - Anti-dilutive securities HTML 30K
(Details)
66: R51 Inventories (Details) HTML 51K
67: R52 Intangible Assets, Net (Details) HTML 68K
68: R53 Accrued Liabilities (Details) HTML 42K
69: R54 LICENSE AGREEMENTS AND COMMITMENTS - MSK License HTML 57K
(Details)
70: R55 LICENSE AGREEMENTS AND COMMITMENTS - LCD33 License HTML 44K
(Details)
71: R56 LICENSE AGREEMENTS AND COMMITMENTS - MabVax/MSK HTML 36K
License (Details)
72: R57 LICENSE AGREEMENTS AND COMMITMENTS - SADA License HTML 38K
Agreement (Details)
73: R58 LICENSE AGREEMENTS AND COMMITMENTS - Summary of HTML 69K
Significant Agreements and Commitments (Details)
74: R59 LICENSE AGREEMENTS AND COMMITMENTS - Other HTML 47K
agreements (Details)
75: R60 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 68K
agreements (Details)
76: R61 LICENSE AGREEMENTS AND COMMITMENTS - Lease costs HTML 37K
(Details)
77: R62 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 46K
maturities (Details)
78: R63 LICENSE AGREEMENTS AND COMMITMENTS - Lease term HTML 33K
and discount rate (Details)
79: R64 LICENSE AGREEMENTS AND COMMITMENTS - Severance HTML 37K
Related Benefits (Details)
80: R65 LICENSE AGREEMENTS AND COMMITMENTS - Legal matters HTML 35K
(Details)
81: R66 STOCKHOLDERS' EQUITY - Authorized, Common and HTML 47K
Preferred Stock (Details)
82: R67 STOCKHOLDERS' EQUITY - Stock grant agreements with HTML 83K
non-employees (Details)
83: R68 STOCKHOLDERS' EQUITY - Issuance of common stock HTML 42K
(Details)
84: R69 SHARE-BASED COMPENSATION - 2015 Plan (Details) HTML 37K
85: R70 SHARE-BASED COMPENSATION - 2018 Plan (Details) HTML 54K
86: R71 SHARE-BASED COMPENSATION - Stock-based HTML 40K
compensation expense - Options (Details)
87: R72 SHARE-BASED COMPENSATION - Stock Option Valuation HTML 37K
(Details)
88: R73 SHARE-BASED COMPENSATION - Stock option activity HTML 67K
(Details)
89: R74 SHARE-BASED COMPENSATION - Stock option grants HTML 58K
(Details)
90: R75 SHARE-BASED COMPENSATION - Stock option HTML 35K
unrecognized compensation (Details)
91: R76 SHARE-BASED COMPENSATION - Restricted Stock Unit HTML 67K
Activity (Details)
92: R77 Related Party Transactions (Details) HTML 47K
93: R78 INCOME TAXES - Loss before income taxes (Details) HTML 44K
94: R79 INCOME TAXES - Current and deferred income taxes HTML 45K
(Details)
95: R80 INCOME TAXES - Reconciliation of Income Taxes HTML 57K
(Details)
96: R81 INCOME TAXES - Deferred assets (Liabilities) HTML 58K
(Details)
97: R82 INCOME TAXES - Net Operating Loss Carryforwards HTML 41K
(Details)
98: R83 INCOME TAXES - Unrecognized tax benefits (Details) HTML 35K
99: R84 Other Benefits (Details) HTML 35K
100: R85 Gain From Sale of Priority Review Voucher HTML 40K
(Details)
101: R86 Subsequent Events (Details) HTML 39K
104: XML IDEA XML File -- Filing Summary XML 193K
102: XML XBRL Instance -- ymab-20221231x10k_htm XML 1.92M
103: EXCEL IDEA Workbook of Financial Reports XLSX 181K
12: EX-101.CAL XBRL Calculations -- ymab-20221231_cal XML 178K
13: EX-101.DEF XBRL Definitions -- ymab-20221231_def XML 793K
14: EX-101.LAB XBRL Labels -- ymab-20221231_lab XML 1.51M
15: EX-101.PRE XBRL Presentations -- ymab-20221231_pre XML 1.24M
11: EX-101.SCH XBRL Schema -- ymab-20221231 XSD 244K
105: JSON XBRL Instance as JSON Data -- MetaLinks 469± 746K
106: ZIP XBRL Zipped Folder -- 0001558370-23-005073-xbrl Zip 974K
EXHIBIT 23
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-230455) of Y-mAbs Therapeutics, Inc. of our report dated March 30, 2023 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Florham Park, NJ
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/30/23 | 8-K | ||
| For Period end: | 12/31/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/29/24 Y-mAbs Therapeutics, Inc. 10-K 12/31/23 101:10M Toppan Merrill Bridge/FA 5/08/23 Y-mAbs Therapeutics, Inc. 10-Q 3/31/23 85:7.4M Toppan Merrill Bridge/FA 3/30/23 Y-mAbs Therapeutics, Inc. S-8 3/30/23 4:168K Toppan Merrill Bridge/FA 3/30/23 Y-mAbs Therapeutics, Inc. S-3 5:975K Toppan Merrill Bridge/FA |